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Purpose
The purpose of this study is to investigate the prognostic value of lymph node (LN) ratio
(LNR) in  patients with breast cancer after neoadjuvant chemotherapy. 
Materials and Methods
This retrospective analysis is based on the data of 814 patients with stage II/III breast cancer
treated with four cycles of doxorubicin/cyclophosphamide followed by four cycles of 
docetaxel before surgery. We evaluated the clinical significance of LNR (3 categories: low
0-0.20 vs. intermediate 0.21-0.65 vs. high 0.66-1.00) using a Cox proportional regression
model. 
Results
A total of 799 patients underwent breast surgery. Pathologic complete response (pCR,
ypT0/isN0) was achieved in 129 patients (16.1%) (hormone receptor [HR] +/human epi-
dermal growth factor receptor 2 [HER2] –, 34/373 [9.1%]; HER2+, 45/210 [21.4%]; triple
negative breast cancer, 50/216 [23.1%]). The mean numbers of involved LN and retrieved
LN were 2.70 (range, 0 to 42) and 13.98 (range, 1 to 64), respectively. The mean LNR was
0.17 (low, 574 [71.8%]; intermediate, 170 [21.3%]; high, 55 [6.9%]). In univariate analysis,
LNR showed significant association with a worse relapse-free survival (3-year relapse-free
survival rate 84.8% in low vs. 66.2% in intermediate vs. 54.3% in high; p < 0.001, log-rank
test). In multivariate analysis, LNR did not show significant association with recurrence after
adjusting for other clinical factors (age, histologic grade, subtype, ypT stage, ypN stage, lym-
phatic or vascular invasion, and pCR). In subgroup analysis, the LNR system had good prog-
nostic value in HR+/HER2– subtype.
Conclusion
LNR is not superior to ypN stage in predicting clinical outcome of breast cancer after neoad-
juvant chemotherapy. However, the prognostic value of the LNR system in HR+/HER2– 
patients is notable and worthy of further investigation.
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Introduction
Neoadjuvant chemotherapy (NCT) is a treatment option
for patients with operable breast cancer, who are candidates
for adjuvant chemotherapy. The equivalency of NCT and 
adjuvant chemotherapy with regard to disease-free survival
and overall survival (OS) was demonstrated in large 
randomized trials [1-3]. NCT has a number of advantages
compared to adjuvant chemotherapy, including downsizing
the tumor to increase the likelihood of breast conservation,
providing in vivo chemosensitivity to oncologists, and 
enabling rapid assessment of the efficacy of new therapeutic
agents. Importantly, the pathologic complete response (pCR)
after NCT has a strong association with improved survival
in patients with aggressive breast cancer subtypes [4]. 
The best established predictor of survival is the absolute
number of involved lymph nodes (LNs) in the axilla follow-
ing NCT, which is in accordance with the ypN stage of the
American Joint Committee on Cancer (AJCC) staging system
[2,5-8]. However, based on previous observations, NCT may
change the histological environment of the axillary area and
reduce the number of retrieved axillary LNs [9,10]. As a 
result, the ypN stage can be underestimated, thereby result-
ing in inadequate treatment. Many studies with adjuvant
chemotherapy suggested that the lymph node ratio (LNR),
the ratio of the number of involved LNs to the total number
of resected LNs, may be a superior prognostic factor than the
pN stage [11-15]. Ahn et al. [14] concluded that LNR may be
superior to the pN stage  as a prognostic factor and can be
used in identification of patient subgroups that may benefit
from adjuvant radiotherapy. Dings et al. [15] reported that
LNR can differentiate populations with poor prognosis
within the same pN stage. In a recent meta-analysis, Liu et
al. [16] reported that LNR was a prognostic predictor for
breast cancer. After analysis of the studies that used 0.2 and
0.65 as the cut-off, the authors confirmed that there was a
dose-response relationship between LNR and OS, disease-
free survival, breast cancer specific survival, and mortality.
However, there are limited data and conflicting results with
regard to the prognostic significance of LNR after NCT
[17,18]. 
In this study, we investigated the prognostic value of LNR
in patients treated with NCT and compared LNR with the
traditional ypN stage of the AJCC in predicting disease 
recurrence. 
Materials and Methods
1. Study population 
This study included 814 consecutive patients from 13 
academic hospitals of the Korean Cancer Study Group. They
were pathologically diagnosed with stage II/III breast cancer
and received treatment with four cycles of doxorubicin/
cyclophosphamide (AC), followed by four cycles of 
docetaxel (DOC) as NCT within a study period from June
2009 to December 2012. Among the 814 patients, 799 had 
undergone surgery and were analyzed. Clinical data were
obtained from the electronic medical records of each hospital.
The data included demographics, past medical history,
pathologic information, radiologic findings, NCT, adjuvant
treatment, recurrence, and survival. Male breast cancer, 
inflammatory breast cancer, recurrent or metastatic breast
cancer, any treatment before NCT, and other coexisting 
malignancies were excluded. This study was approved by
the Institutional Review Board at Seoul National University
Bundang Hospital (Seongnam, Korea) and participating 
institutions. 
2. Treatment and tumor assessment
All patients were treated with four cycles of AC (doxoru-
bicin 60 mg/m2 on day 1 and cyclophosphamide 600 mg/m2
on day 1 every 21 days) followed by four cycles of DOC 
(75 mg/m2 on day 1 every 21 days). In patients with overex-
pression or amplification of human epidermal growth factor
receptor 2 (HER2), trastuzumab was incorporated into the
adjuvant treatment and administered for 1 year after surgery.
The clinical response to NCT was evaluated every four 
cycles, using ultrasound or magnetic resonance imaging in
accordance with the Response Evaluation Criteria in Solid
Tumors (RECIST) ver. 1.1. 
Pathological assessment was performed with core biopsy
samples or surgical specimens of primary tumors by a
pathologist at each institution. Immunohistochemistry (IHC)
was performed for the estrogen receptor, progesterone 
receptor, and HER2. In patients with HER2 IHC score of 2+,
HER2 amplification status was confirmed by fluorescent in
situ hybridization or silver in situ hybridization. pCR was 
defined as ypT0N0 (absence of invasive cancer and in situ
cancer in the breast and axillary nodes) or ypT0/isN0 
(absence of invasive cancer in the breast and axillary nodes).
From the pathological report of the surgical specimen, LNR
was calculated as the ratio of the number of involved LNs to
the number of total retrieved LNs. LNR was categorized 
according to three groups based on previous findings: low
(LNR, 0 to 0.20), intermediate (0.21 to 0.65), and high (0.66 to
1.00) [12-14].
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3. Statistical analysis
Data were described as frequencies (%), or means and  
medians (range). An independent two-sample t test was used
for analysis of continuous variables, and chi-square test for
categorical variables. The primary end point was relapse-free
survival (RFS), calculated from the start of NCT to recurrence
of breast cancer. Patients who were relapse free at the last
contact were censored at the last follow-up date. The second-
ary end points were the rate of distant recurrence and OS.
OS was determined from the initial NCT to death from any
cause. The Kaplan-Meier method was used for estimation of
survival outcomes and the log-rank test was used for deter-
mination of differences between the groups. Cox propor-
tional hazard regression analysis was used for estimation of
hazard ratios and 95% confidence intervals (CIs). Variables
with statistical significance (p < 0.05) in univariate analysis
were included as covariates in multivariate analysis. A value
of p < 0.05 was considered to indicate statistical significance,
and all resulting p-values were two sided. All statistical 
procedures were performed using SPSS ver. 18.0 (SPSS Inc.,
Chicago, IL). 
Results
1. Patient characteristics  
A total of 799 patients were included in our study 
(Table 1). The median age was 45 years (range, 16 to 74
years), and the majority (88.1%) underwent axillary LN 
dissection. Before surgery, 687 patients (85.9%) had under-
gone fine needle aspiration biopsy or sentinel LN biopsy
(n=19, 2.4%) for axillary staging. Almost all patients
(741/799, 92.8%) received eight cycles of NCT. The pCR rate
and LN status according to subtype of breast is shown in
Table 2. The overall pCR (T0/isN0) rate was 16.1% (129/799);
9.1% (34/373) in HR+/HER2– patients, 21.4% (45/210) in
HER2+ patients, and 23.1% (50/216) in triple negative breast
cancer (TNBC) patients. Among the pathologically con-
firmed LN+ patients (n=622), pathologic axillary LN clear-
ance (ypN0) was achieved in 243 patients (39.1%). The
median numbers of involved LNs and retrieved LNs were
one (range, 0 to 42) and 13 (range, 1 to 64), respectively. Most
patients (759/799, 95%) had more than four retrieved LNs
after surgery (Supplementary Table 1). The median and
mean numbers of LNR were 0.07 and 0.17, respectively.
When using the LNR classification, 574 patients (71.8%)
were categorized as low (LNR, 0 to 0.20), 170 (21.3%) as 
intermediate (0.21 to 0.65), and 55 (6.9%) as high (0.66 to
Table 1. Baseline characteristics of patients
Characteristic No. (%)
Age (yr)
Median (range) 45 (16-74)
ECOG PS 
0 470 (58.8)
1 327 (40.9)
2 2 (0.3)
Histology
Ductal 762 (95.4)
Lobular 15 (1.9)
Others 22 (2.7)
Histologic grade
1 32 (4).0
2 379 (47.4)
3 304 (38).0
Unknown 84 (10.5)
Tumor size at diagnosis (cm)
Mean±SD 4.3±2.36
Median (range) 3.8 (0.8-20)
cT stage 
0 6 (0.8)
1 54 (6.8)
2 440 (55.1)
3 238 (29.8)
4 61 (7.6)
cN stage
0 42 (5.3)
1 379 (47.4)
2 238 (29.8)
3 140 (17.5)
ER receptor 
Positive 454 (56.8)
Negative 345 (43.2)
PR receptor 
Positive 384 (48.1).0
Negative 415 (51.9).0
Subtype 
HR+/HER2– 373 (46.7).0
HER2+ 210 (26.3).0
TNBC 216 (27).0
ECOG, Eastern Cooperative Oncology Group; PS, 
performance status; SD, standard deviation; ER, estrogen
receptor; PR, progesterone receptor; HR, hormone recep-
tor; HER2, human epidermal growth factor receptor 2;
TNBC, triple negative breast cancer.
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1.00). Patients with HR+/HER2– subtype had a significantly
lower rate of ypN0 stage compared with other subtypes
(28.4% vs. 47.6% in HER2 and 59.7% in TNBC, p < 0.001). 
Approximately two-thirds of patients with HR+/ HER2–
subtype were categorized as the low LNR group (63.4% in
HR+/HER2– vs. 77.6% in HER2 and 80.6% in TNBC, 
p < 0.001). 
2. Survival and relapse according to axillary LN status
RFS and OS were evaluated with a median follow-up 
period of 31.0 months. With the LNR classification, the 3-year
RFS rates were 84.8%, 66.2%, and 54.3% in low, intermediate,
and high groups, respectively (p < 0.001) (Fig. 1A). The esti-
mated 3-year OS rates were 92.7%, 87.1%, and 79.3% in the
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Fig. 1. Survival of patients according to lymph node ratio (LNR) status: relapse-free survival (A) and overall survival (B).
Table 2. Pathological response and lymph node status after NCT 
Variable Total HR+/HER2– HER2+ TNBC p-value
No. of lymph nodes 
Involved 2.70 (0-42). 3.12 (0-41) 2.25 (0-30) 2.42 (0-42) 0.083
Retrieved 13.98 (1-64).0 14.20 (1-47)0 13.62 (1-38)0 13.96 (1-64)0 0.737
ypN stage by AJCC
0 335 (41.9) 106 (28.4) 100 (47.6) 129 (59.7) < 0.001
1 286 (35.8) 166 (44.5) 71 (33.8) 49 (22.7)
2 116 (14.5) 71 (19) 27 (12.9) 18 (8.3)
3 62 (7.8) 30 (8)0 12 (5.7) 20 (9.3)
Lymph node ratio 
Low 574 (71.8) 236 (63.4) 163 (77.6) 174 (80.6) < 0.001
Intermediate 170 (21.3) 108 (29)0 34 (16.2) 28 (16.5)
High 55 (6.9) 28 (7.5) 13 (6.2) 14 (6.5)
pCR (ypT0/isN0)
Yes 129 (16.1) 34 (9.1) 45 (21.4) 50 (23.1) < 0.001
No 670 (83.9) 339 (90.9) 165 (78.6) 166 (76.9)
Values are presented as mean (range) or number (%). NCT, neoadjuvant chemotherapy; HR, hormone receptor; HER2, human
epidermal growth factor receptor 2; TNBC, triple negative breast cancer; AJCC, American Joint Committee on Cancer; pCR,
pathologic complete response.
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low, intermediate, and high groups, respectively (p=0.011)
(Fig. 1B). Using the ypN-stage classification, the 3-year RFS
rates were 88.1%, 80.8%, 61.8%, and 48.1% in ypN0, ypN1,
ypN2, and ypN3 stages, respectively (p < 0.001). Probabilities
of 3-year OS were 94.6%, 91.5%, 87.3%, and 69.6% in ypN0,
ypN1, ypN2, and ypN3 stage, respectively (p < 0.001). 
To examine the pattern of relapse in accordance with LNR
status, disease recurrence was classified as locoregional, 
distant only, and locoregional with distant relapse (Supple-
mentary Table 2). The increase of LNR showed significant
association with the distant failure rate (9.5% in low group
vs. 18.2% in intermediate group vs. 27.3% in high group, 
chi-square p < 0.001).
3. Survival analysis
Among the variables analyzed in the univariate Cox
model, pCR status, histologic grade, subtype by IHC, ypT
stage, ypN stage, lymphovascular invasion (LVI), and LNR
classification showed significant association with RFS in all
patients. The LNR classification was not an independent 
predictor for RFS in the multivariate model adjusted for age,
pCR status, histologic grade, subtype by IHC, ypT stage,
ypN stage, and LVI (p=0.954) (Table 3). To exclude the 
possibility of any confounding effect, we constructed two
multivariate models with either ypN stage or LNR classifi-
cation. Both ypN stage and LNR classification were inde-
pendent predictors for RFS in each model. By calculating the
log likelihood chi-squares of each model, we were able to
compare the fit of each model (higher value indicates a more
predictive model). However, the values of log likelihood 
chi-squares of both models were similar (Supplementary
Table 3).
4. Prognostic value of LNR according to subtype by IHC
In HR+/HER2– patients, a statistically significant differ-
ence in RFS was observed in accordance with LNR status
during the follow-up period (LNR-low vs. LNR-intermedi-
ate, p=0.045; LNR-low vs. LNR-high, p=0.001; LNR-interme-
diate vs. LNR-high, p=0.027) (Fig. 2). In HER2+ and TNBC
patients, LNR-low showed association with better RFS than
LNR-intermediate or LNR-high (LNR-low vs. LNR-interme-
diate, p < 0.001 in HER2+ and p < 0.001 in TNBC; LNR-low
vs. LNR-high, p=0.001 in HER2+ and p < 0.001 in TNBC; log-
rank test) (Fig. 2). However, no significant difference in RFS
Table 3. Multivariate analysis for relapse-free survival of patients
Variable Hazard ratio 95% CI p-value
Age (< 50 yr vs. > 50 yr) 0.77 0.53-1.11 0.157
Histologic grade 1 1.0 0.001
Histologic grade 2 1.2 0.37-3.92
Histologic grade 3 2.59 0.78-8.57
Histologic grade NA 1.27 0.33-4.94
Subtype: HR+/HER2– 1.0 < 0.001
Subtype: HER2+ 1.69 1.02-2.79
Subtype: TNBC 4.97 3.24-7.61
pCR (ypT0/isN0) vs. non-pCR 0.26 0.08-0.86 0.027
ypT stage 0 1.0 < 0.001
ypT stage 1 0.85 0.39-1.83
ypT stage 2 1.96 0.90-4.24
ypT stage 3 1.95 0.69-3.95
ypT stage 4 5.93 1.63-21.58
ypN stage 0 1.0 0.035
ypN stage 1 1.72 1.04-2.84
ypN stage 2 2.69 1.27-5.71
ypN stage 3 3.39 1.43-8.01
Lymphovascular invasion (yes vs. no) 1.5 1.02-2.22 0.040
LNR low (0-0.20) 1.0 0.954
LNR intermediate (0.21-0.65) 1.01 0.55-1.86
LNR high (0.66-1.00) 1.12 0.48-2.59
CI, confidence interval; NA, not available; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC,
triple negative breast cancer; pCR, pathologic complete response; LNR, lymph node ratio.
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was observed between LNR-intermediate and LNR-high
(LNR-intermediate vs. LNR-high, p=0.990 in HER2+ and
p=0.413 in TNBC) (Fig. 2). The LNR classification was not an
independent predictor for RFS in the multivariate model in
each subtype (Supplementary Table 4).
Discussion
In this study, we demonstrated that the axillary LN status,
either ypN stage or LNR, is of prognostic value in breast 
cancer patients treated with NCT. Patients with higher LNR
had poorer RFS and OS. In comparison of the value of log
likelihood chi-squares between two models, the prognostic
power of LNR after NCT, using the cut-off points of 0.20 and
0.65, appears to be similar to that of the current ypN stage in
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Fig. 2. Relapse-free survival of patients according to lymph node ratio (LNR) status and subtype: hormone receptor
+/human epidermal growth factor receptor 2 (HER2) – (A), HER2+ (B), and triple negative breast cancer (C).
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our patient cohort. To the best of our knowledge, this study
is the largest study to date addressing the prognostic value
of LNR in patients uniformly treated with eight courses of 
sequential anthracycline-taxane–based NCT. 
It should be noted that the number of retrieved and exam-
ined LNs is influenced by NCT [9,10]. In our study, most 
patients (92.8%) completed the preplanned eight cycles of
NCT, while only three cycles of NCT were utilized in previ-
ous studies [17,18]. In the most recent study, Chen et al. [19]
reported a better prognostic value of LNR than ypN stage in
patients treated with median three cycles of NCT. The pCR
rate of 16.1% in our study is higher than that of other studies
(range, 6.8% to 10.7%) reporting that the LNR system is 
superior to ypN stage [17,19]. The longer duration with more
effective NCT in the current study may result in a lower
number of involved LNs than that of the two previous stud-
ies (Supplementary Table 5). The reason for the consistent 
results with regard to the prognostic significance of LNR in
an adjuvant setting compared to the conflicting results in a
neoadjuvant setting may be derived in part from less 
involvement of LNs in studies with NCT. We suppose that
there might be an inverse correlation between the efficacy of
NCT and prognostic impact of LNR. 
We observed a low pCR rate (9.1%) and good separation
of RFS curves with the LNR system in HR+/HER2– patients.
Conversely, a high pCR rate (21.4% in HER2+ and 23.1% in
TNBC) and overlapping RFS curves were observed in HER2
and TNBC patients. These findings are in line with those of
recent studies reporting a strong dependence on the intrinsic
subtype for a relationship between pCR rate and survival
[4,20,21]. In addition, the prognostic value of the LNR system
in HR+/HER2– patients is notable because it could have a
role in selection of high-risk patients for adjuvant radiother-
apy or prolonged duration of adjuvant endocrine therapy.
Tausch et al. [22], who reported that LNR was an additional
prognostic factor in patients with one to three involved LNs
after mastectomy, suggested LNR as an indicator for post-
mastectomy radiotherapy, which is still controversial in 
patients with one to three LNs [23]. Currently, identification
of patients who might benefit from extended adjuvant 
endocrine therapy is not possible. The findings by Sestak et
al. [24] suggest that clinical factors, including nodal status
(positive vs. negative) and tumor size (> 2 cm vs. < 2 cm), are
important prognostic factors even beyond the initial 5 years
of adjuvant endocrine therapy. Therefore, further evaluation
to determine whether the LNR system can add prognostic
value and complement the current nodal staging system in
HR+/HER2– patients treated with NCT is worthwhile. 
Many studies have documented the usefulness of LNR;
however, the thresholds used for defining low- and high-risk
groups varied [11]. Vinh-Hung et al. [12], who investigated
the “optimal” cut-off values for categorizing a continuous
variable of LNR with minimal loss of information, analyzed
the data for 1,829 women with node-positive breast cancer
and identified two LNR cut-off points, 0.20 and 0.65, which
predicted breast cancer survival more adequately than pN
categories. Compared with the pN classification, the LNR
classification was more robust without overlapping CIs and
without crossing of survival curves between the intermediate
(LNR, 0.21 to 0.65) and high (LNR, > 0.65) risk groups. How-
ever, the cut-off points of 0.20 and 0.65 were not validated in
patients treated with NCT, while the values were able to
identify poor prognostic patients after primary surgery 
[13-15]. In our study population, LNR classification did not
show an independent prognostic significance when the ypN
stage was included in the multivariate model. The superior-
ity of LNR classification over the current ypN stage was not
supported by this study. 
We note that our study had several limitations. First, its
retrospective nature may have resulted in selection bias. To
minimize this bias, however, we included consecutive 
patients from the database of participating institutions. 
Second, HER2 targeted therapy was not included in neoad-
juvant treatment, but administered as adjuvant treatment 
because neoadjuvant trastuzumab was not reimbursed at the
time of the study in Korea. Therefore, compared to other
studies, the pCR rate may have been relatively lower in our
patients, without impact of survival. Last, the inclusion of
cN0 patients in the current study raised the possibility that
these patients underwent inadequate axillary surgery. How-
ever, two thirds of patients (28/42, 66.7%) had undergone
axillary LN dissection for their axillary staging. 
Conclusion
In conclusion, our findings suggest that LNR is not supe-
rior to ypN stage in predicting clinical outcome of breast 
cancer patients after NCT. Both LNR and ypN stage had sim-
ilar prognostic values after NCT. Findings from the 
subgroup analysis suggest that LNR might provide some 
additional prognostic information in HR+/HER2– patients
after NCT, compared to HER2+ or TNBC patients. Further
studies are needed to evaluate the optimal cut-off points and
prognostic value of LNR in breast cancer patients treated
with NCT.
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